Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: Parallel study of 81 patients

Blanca Xicoy, Josep Maria Ribera, Markus Müller, Olga García, Christian Hoffmann, Albert Oriol, Marcus Hentrich, Carlos Grande, Jan Christian Wasmuth, Jordi Esteve, Jan Van Lunzen, Eloy Del Potro, Heribert Knechten, Salut Brunet, Christoph Mayr, Lourdes Escoda, Philipp Schommers, Natalia Alonso, Ferran Vall-Llovera, Montserrat PérezMireia Morgades, José González, Angeles Fernández, Jan Thoden, Nicola Gökbuget, Dieter Hoelzer, Gerd Fätkenheuer, Christoph Wyen

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)

Abstract

© 2014 Informa UK, Ltd. The results of intensive immunochemotherapy were analyzed in human immunodeficiency virus (HIV)-related Burkitt lymphoma/leukemia (BLL) in two cohorts (Spain and Germany). Alternating cycles of chemotherapy were administered, with dose reductions for patients over 55 years. Eighty percent of patients achieved remission, 11% died during induction, 9% failed and 7% died in remission. Four-year overall survival (OS) and progression-free survival (PFS) probabilities were 72% (95% confidence interval [CI]: 62-82%) and 71% (95% CI: 61-81%). CD4 T-cell count < 200/μL and bone marrow involvement were associated with poor OS (hazard ratio [HR] 3.2 [1.2-8.3] and HR 2.7 [1.1-6.6]) and PFS (HR 3.5 [1.3-9.1] and HR 2.4 [1-5.7]), bone marrow involvement with poor disease-free survival (DFS) (HR 14.4 [1.7-119.7] and Eastern Cooperative Oncology Group (ECOG) score > 2 (odds ratio [OR] 11.9 [1.4-99.9]) with induction death. In HIV-related BLL, intensive immunochemotherapy was feasible and effective, but toxic. Prognostic factors were performance status, CD4 T-cell count and bone marrow involvement.
Original languageEnglish
Pages (from-to)2341-2348
JournalLeukemia and Lymphoma
Volume55
Issue number10
DOIs
Publication statusPublished - 1 Oct 2014

Keywords

  • Burkitt lymphoma or leukemia
  • HIV infection
  • Prognostic factors
  • Specific chemotherapy

Fingerprint

Dive into the research topics of 'Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: Parallel study of 81 patients'. Together they form a unique fingerprint.

Cite this